Multifunctional chitosan-based nanoparticles were designed and synthesized by photosensitizer (PS) AZA-BODIPY grafting water-soluble chitosan as nanoshells and then loaded drug methotrexate (MTX) into the nanoshells, which generated chemotherapy, photothermal therapy (PTT), photodynamic therapy (PDT) and imaging into one system for synergistic therapy in vitro. The nanoshells in this designed nanostructure can serve as drug carriers to increase solubility, reduce toxicity and enhance the efficacy of synergistic PTT and PDT. Cell-viability indicated the low toxicity and safety of chitosan-based AZA-BODIPY nanoshells as carrier materials and the low-drug dosage of chitosan-based nanoparticles (half-maximal inhibitory concentration, IC₅₀ = 34.5 μg/mL) is lower than that of pure drug MTX (IC₅₀ = 56.9 μg/mL). Under light irradiation, photothermal temperature and MTT studies show that nanoparticles produce reactive oxygen species and exhibit photothermal conversion efficiency (38.3%). Thus, this study provides a multifunctional nanoparticle with chemotherapy, photothermal, photodynamic and imaging, synergistic therapy and diagnose for cancer treatment.

以光敏剂（PS）AZA-BODIPY接枝水溶性壳聚糖为纳米壳，然后将甲氨蝶呤（MTX）负载到纳米壳中，设计并合成了多功能的壳聚糖纳米颗粒，产生了化学疗法，光热疗法（PTT），光动力疗法（PDT） ），然后将其成像为一个用于体外协同治疗的系统。这种设计的纳米结构中的纳米壳可以用作药物载体，以增加溶解度，降低毒性并增强PTT和PDT的协同作用。细胞生存能力表明，壳聚糖基AZA-BODIPY纳米壳作为载体材料的毒性和安全性低，壳聚糖基纳米颗粒的低药物剂量（半数最大抑制浓度，IC ₅₀  = 34.5μg/ mL）低于该值。纯药物MTX（IC ₅₀ = 56.9μg/ mL）。在光照射下，光热温度和MTT研究表明，纳米粒子产生活性氧，并表现出光热转化效率（38.3％）。因此，本研究提供了具有化学疗法，光热，光动力和成像，协同治疗以及癌症治疗诊断的多功能纳米颗粒。